<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429806</url>
  </required_header>
  <id_info>
    <org_study_id>ERC-213</org_study_id>
    <nct_id>NCT00429806</nct_id>
  </id_info>
  <brief_title>DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy</brief_title>
  <official_title>DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy-Phase I Randomized,Placebo-Controlled, Double-Blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the systemic bioavailability of DHEA and its
      metabolites and the pharmacokinetics of vaginal suppositories at four different DHEA
      concentration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Humans, are unique among animal species in having adrenals that secrete large amounts of the
      inactive precursor steroids dehydroepiandrosterone (DHEA) and especially its sulfate DHEA-S.
      The marked reduction in the formation of DHEA-S by the adrenals during aging results in a
      dramatic fall in the formation of androgens and estrogens in peripheral target tissues, a
      situation that has been proposed to be associated with age-related diseases including skin
      atrophy, insulin resistance and obesity. Much attention has been given to the benefits of
      DHEA administered to postmenopausal women, especially on the bone, skin, vagina and well
      being after oral as well as percutaneous administration of the precursor steroid.

      Therefore, this study proposes to evaluate the systemic bioavailability and the effectiveness
      of 1.3 mL vaginal suppositories of DHEA at 4 different concentrations (0.0%, 0.5%, 1.0% et
      1.8%) following 1 week administration of vaginal suppositories in post-menopausal women with
      vaginal atrophy. This is a phase I, randomized, placebo-controlled, double-blind study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The evaluation of the systemic bioavailability of DHEA and its metabolites.</measure>
    <time_frame>Day 1-2 and Day 7-8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of vaginal suppositories at four different DHEA concentrations.</measure>
    <time_frame>Day 1-2 and Day 7-8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerance of the suppositories.</measure>
    <time_frame>Day 1 to Day 8 (plus follow-up of Adverse Events for 30 days after last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of treatment on maturation index and value</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Vaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo suppository; once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHEA 0.50%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHEA 0.50% (6.5 mg) suppository; once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHEA 1.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHEA 1.0% (13 mg) suppository; once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHEA 1.8%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHEA 1.8% (23.4 mg) suppository; once daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA</intervention_name>
    <description>DHEA</description>
    <arm_group_label>DHEA 0.50%</arm_group_label>
    <arm_group_label>DHEA 1.0%</arm_group_label>
    <arm_group_label>DHEA 1.8%</arm_group_label>
    <other_name>dehydroepiandrosterone; prasterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women,

          -  Experiencing one symptom of vaginal atrophy (vaginal dryness, vaginal and/or vulvar
             irritation/itching, dysuria, vaginal pain associated with sexual activity or vaginal
             bleeding associated with sexual activity,

          -  Women having a low maturation index and a vaginal pH above 5,

          -  Endometrial thickness of 4 mm or less at transvaginal ultrasonography,

          -  Body weight within 18.5 and 32.0 according to body mass index.

        Exclusion Criteria:

          -  Undiagnosed abnormal genital bleeding,

          -  Active or history of thromboembolic disease,

          -  Significant metabolic or endocrine disease,

          -  Significant complication on previous hormonal therapy,

          -  Use of hormonal implants within 6 months prior to study entry,

          -  Use of oral estrogen, progestin or DHEA in the 8 weeks prior to baseline,

          -  Use of natural (phytoestrogens) or herbal products in the 2 weeks prior to baseline,

          -  Chronic use of corticosteroids,

          -  Hypertension not controlled by standard therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernand Labrie, MD, Ph D</last_name>
    <role>Study Chair</role>
    <affiliation>CHUL Research Center Director</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cusan Leonello, MD Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUL Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique des traitements hormonaux CHUL Research Center</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol. 2008 Sep;111(3-5):178-94. doi: 10.1016/j.jsbmb.2008.06.003. Epub 2008 Jun 12. Erratum in: J Steroid Biochem Mol Biol. 2008 Nov;112(1-3):169.</citation>
    <PMID>18598765</PMID>
  </results_reference>
  <results_reference>
    <citation>Labrie F, Martel C, Bérubé R, Côté I, Labrie C, Cusan L, Gomez JL. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. J Steroid Biochem Mol Biol. 2013 Nov;138:359-67. doi: 10.1016/j.jsbmb.2013.08.002. Epub 2013 Aug 14.</citation>
    <PMID>23954500</PMID>
  </results_reference>
  <results_reference>
    <citation>Labrie F, Martel C. A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values. Horm Mol Biol Clin Investig. 2017 Feb 1;29(2):39-60. doi: 10.1515/hmbci-2016-0042.</citation>
    <PMID>27997350</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2007</study_first_submitted>
  <study_first_submitted_qc>January 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaginal atrophy</keyword>
  <keyword>DHEA</keyword>
  <keyword>Prasterone</keyword>
  <keyword>Menopause</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

